Investigators calculated that the new assay, which includes 67 SNPs, could offer a 50 percent improvement over previous methods if used in newborn screening.
The company aims to launch the test, which it believes will improve monitoring and treatment of patients with diabetes, in China within the next two years.
The firm plans to seek full commercial approval for its assay, which integrates biomarker identification with a patient's electronic medical record, later this year.
LabCorp and TACHC will use data analytics and clinical decision support tools to improve the care of patients with chronic kidney disease and diabetes.
The lab analytics service provides insurers with guidance aimed at helping them achieve improvements in quality performance metrics.
The project builds on a collaboration between Bio-Rad and Genetic Analysis using the GA-map clinical test for gut dysbiosis.
The blood test provides a simple alternative to complex methods of insulin resistance testing used primarily for research, the company said.
The new services geared toward wellness testing enable patients to order test kits without visiting their doctor.
Becton Dickinson got clearance for a platform and test for the rapid identification and determination of antimicrobial susceptibility of gram-negative bacteria.
The National Institutes of Health Commercial Accelerator Program helps small healthcare and life science companies bring their products to market.